EarningsQ2 2026 Earnings Report
MX:OCGN Q2 2026 EPS Results
Actual EPS-$1.27
Consensus EPS-$0.96
Beat/MissMissed by -$0.31
One Year Ago EPS-$0.90
MX:OCGN Q2 2026 Revenue Results
Actual Revenue$26.93M
Expected Revenue$16.09M
Beat/MissBeat by +$10.84M
YoY Revenue Growth+8.38%
Earnings Announcement Details
QuarterQ2 2026
Date08/06/2026
TimeBefore Open
Conference CallThursday, August 6, 2026
MX:OCGN Upcoming Earnings
Ocugen's next earnings date is estimated for November 10, 2026, based on past reporting schedules.
Q2 2026 Earnings Call Audio
MX:OCGN Q2 2026 Earnings Call
0:00 / 0:00
Q2 2026 Earnings Slide Deck
No slide deck is available for this earnings event.
Q2 2026 Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed multiple significant clinical and regulatory advances — FDA clearance to start the Phase 3 GA trial with RMAT designation, strong Phase II efficacy signals for OCU410, completed enrollments and clear timelines for Phase III readouts for OCU400 and OCU410ST, manufacturing PPQs complete, a $130M financing and cash runway into 2028, and a MENA partnership — all material execution milestones. Offsetting these positives are rising operating expenses and a larger reported net loss per share, continued dependence on additional financing levers (which could be dilutive), and customary regulatory/timing and commercialization uncertainties. Overall, the operational and clinical progress and strengthened balance sheet outweigh the financial and execution risks discussed on the call.Company Guidance
Regulatory Milestones for OCU410 (GA)
FDA cleared the Phase 3 ArMaDa3 registrational trial for OCU410 to initiate dosing and granted RMAT designation. The Phase III is planned as a global ~237-subject adaptive trial powered at 95% with initiation targeted by September 2026 and BLA/MAA filings targeted for 2028.
Positive Phase II Efficacy Signals for OCU410
Phase II ArMaDa (optimal dose) showed a statistically significant 31% reduction in GA lesion growth (for lesions 2.5–17.5 mm^2) and 27% preservation of the ellipsoid zone at 12 months versus control; no drug-related serious adverse events reported.
Progress and Timelines for OCU400 (RP) and OCU410ST (Stargardt)
OCU400 liMeliGhT Phase III enrollment complete (140 patients randomized 2:1); top line Phase III data expected Q1 2027 with potential approval in Q4 2027. OCU410ST Phase II/III GARDian3 enrollment and dosing complete (63 participants); interim outcome decision for first 50% at 8 months expected in Q3 2026 and top line data in Q2 2027 with BLA submission mid-2027.
Manufacturing and CMC Readiness
Process Performance Qualification (PPQ) batches are complete supporting BLA and commercial launch supplies for OCU400, indicating manufacturing readiness ahead of potential approvals.
Capital Raise Extends Runway into 2028
Closed $130 million convertible notes financing; cash, cash equivalents and restricted cash totaled $100.4 million as of June 30, 2026, which management states extends the company’s cash runway into 2028 and supports advancement of three late-stage programs.
Clinical Experience and Safety Profile
Across the pipeline (Phase I through Phase III) Ocugen has treated more than 325 patients, including EAP and multiple doses/indications, and has not observed any drug-related serious adverse events to date.
Business Development and Global Strategy
Signed a binding term sheet with Roots Pharmaceutical (and partner Al-Dhow) for exclusive rights to OCU400 in the Middle East & North Africa (MENA); active BD efforts for additional regional commercialization partnerships. Company is building global commercial capabilities (CMS/reimbursement discussions, centers of excellence, patient journey mapping, supply chain and marketing/sales infrastructure).
Large Addressable Markets
Management cites large commercial opportunities: GA (~2–3 million patients in U.S. and Europe), RP (~300,000 in U.S. and Europe), Stargardt (~100,000 in U.S. and Europe; ~1 million globally), positioning a broad market opportunity for a gene-agnostic, one-time treatment platform.
MX:OCGN Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed